✦ LIBER ✦

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

✍ Scribed by D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia LoRusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw

Book ID: 118046558
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 310 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70344-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9084 POSTER A Global Phase 2 Study Inclu

9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)

✍ Kim, D.W.; Blackhall, F.; Soria, J.C.; Solomon, B.; Camidge, D.R.; Riely, G.J.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Drug-induced reduction in estimated glom

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

✍ Brosnan, Evelyn M.; Weickhardt, Andrew J.; Lu, Xian; Maxon, Delee A.; Barón, Ann 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 520 KB

Safety and activity of alectinib against

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

✍ Gadgeel, Shirish M; Gandhi, Leena; Riely, Gregory J; Chiappori, Alberto A; West, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 385 KB

369 Timing of responses to crizotinib (P

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

✍ B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Cost-Effectiveness of EML4-ALK Fusion Te

Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)

✍ Djalalov, S.; Beca, J.; Hoch, J.S.; Krahn, M.D.; Tsao, M.S.; Cutz, J.C.; Leighl, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Activity of gemcitabine in patients with

Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

✍ U. Gatzemeier; F.A. Shepherd; T. Le Chevalier; P. Weynants; B. Cottier; H.J.M. G 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 839 KB